Valeant Pharmaceuticals International (NYSE:VRX)
A global specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products, primarily in the areas of neurology, infectious disease, and dermatology.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
eksummers620
(73.32)
Submitted: 12/29/2011 9:29:52 PM :
Start Price:
$46.10
VRX Score:
-2.69
This is principal holding of the Sequoia Fund.
Recs
Retire20150
(56.26)
Submitted: 9/23/2011 10:26:10 PM :
Start Price:
$38.33
VRX Score:
+7.76
Generics are en vogue.
Recs
TomFoolNC
(97.39)
Submitted: 9/18/2011 11:25:48 PM :
Start Price:
$41.13
VRX Score:
+4.08
picks its spots, Bob Goldfarb
Recs
gatzbp
(72.57)
Submitted: 8/18/2011 1:26:05 PM :
Start Price:
$39.87
VRX Score:
+2.81
I like picking up healthcare after this pullback. Good model of cost cutting which should work regardless of who is in power in the government.
Recs
GingerInOz
(31.72)
Submitted: 6/20/2011 12:01:30 AM :
Start Price:
$50.42
VRX Score:
-10.74
This company has pharmaceuticals in the pipeline that are already making the medical community enticed and waiting for FDA approval. Its performance thus far has been stellar.
Recs
LordDividend
(< 20)
Submitted: 5/4/2011 10:59:34 AM :
Start Price:
$48.69
VRX Score:
-1.27
Who will the CEO target next?
Recs
thunderhawke23
(34.44)
Submitted: 3/30/2011 10:17:51 AM :
Start Price:
$48.84
VRX Score:
-3.31
strong CEO
Recs
outsidernone
(< 20)
Submitted: 12/1/2010 3:02:15 PM :
Start Price:
$26.97
VRX Score:
+66.69
Approval of new drug
Recs
jsgant13
(96.11)
Submitted: 11/15/2010 12:39:38 PM :
Start Price:
$25.17
VRX Score:
+79.19
VALUEACT HOLDING
Recs
Recs
up82870
(< 20)
Submitted: 9/26/2010 2:33:44 PM :
Start Price:
$25.94
VRX Score:
+67.73
They are being honest!
Recs
rathrbsrfng
(51.97)
Submitted: 5/17/2010 10:31:28 AM :
Start Price:
$18.67
VRX Score:
+138.73
Good momentum
Recs
BSHumphreyII
(88.44)
Submitted: 4/28/2010 10:55:00 PM :
Start Price:
$17.33
VRX Score:
+164.63
Valeant is a high-momentum growth pick. They've had monster EPS growth in the past, but that has slowed somewhat. Sales growth is steady in the low 30s, though. Their new anti-epilepsy drug Retigabine is moving through the pipeline and has the potential to be a huge winner.
There's some serious risk with the potential reward though, so be careful. Valeant aggressive acquisition strategy could be spreading them thin, and they're using significantly more leverage than their competitors in the process. One wrong step could make Valeant's sweet fundamentals turn sour in a hurry.
All said, though, VRX is a big growth story that is quickly moving up in the pharmaceutical world. It should be worth a buy, but stay on top of the news and do your homework.
Recs
mrbill6
(66.59)
Submitted: 10/29/2009 8:16:43 PM :
Start Price:
$11.71
VRX Score:
+282.58
moneycentral rated: 10, navallier rated:A
Recs
Beebzer
(90.33)
Submitted: 5/20/2009 1:34:09 AM :
Start Price:
$9.12
VRX Score:
+377.48
Building a portfolio based on insider cluster buys.
Recs
crimfunk
(81.60)
Submitted: 2/2/2008 1:21:34 AM :
Start Price:
$4.38
VRX Score:
+993.60
undervalued, EPS 5 Year Growth (%) 199.82
Recs
hennessy7
(< 20)
Submitted: 10/10/2007 11:27:13 AM :
Start Price:
$6.19
VRX Score:
+683.32
I was long on this stock until my stop loss triggered. Looks like it may trend down before coming back up. Not willing to bet my $ but I will put it on CAPS.
Recs
henncoop
(98.12)
Submitted: 5/16/2007 1:30:17 PM :
Start Price:
$6.20
VRX Score:
+678.87
near 52 week low
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 18 of 18